CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the company will be exhibiting at the 83rd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting to be held in Washington, D.C. May 2-6, 2015. As the premier neurological society, the AANS expects over 3,000 attendees at this year’s meeting.
The InVivo exhibit will focus on increasing awareness about the ongoing Investigational Device Exemption (IDE) pilot trial of its Neuro-Spinal Scaffold in subjects with acute spinal cord injury. Members of InVivo’s management will be displaying and explaining intraoperative videos from the first two subjects enrolled in the trial thus far. In addition, intraoperative videos evaluating surgical implantation of the investigational Neuro-Spinal Scaffold in a porcine model of acute spinal cord injury at various early time points will be presented.
Of note, InVivo Therapeutics’ neurosurgeon collaborators will be presenting preclinical and clinical data at this medical meeting. James Guest, M.D., Ph.D., Associate Professor of Clinical Neurological Surgery at the University of Miami Miller School of Medicine, will be giving an oral presentation highlighting the findings from the porcine study. Alexander Ropper, M.D., neurosurgeon from the Barrow Neurological Institute who helped implant the Neuro-Spinal Scaffold into the first subject of the company’s pilot trial, will be presenting an E-poster describing the case and the previously disclosed three-month follow-up data.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “The AANS Annual Scientific Meeting is one of the premier neurosurgical conferences and I am pleased we are a part of it. The InVivo team looks forward to continuously expanding our neurosurgical network.”
For more information about the 83rd AANS Annual Scientific Meeting, please visit their website: http://www.aans.org/annualmeeting.aspx
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an IDE pilot study for the treatment of subjects with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.